ライフサイエンスコーパス: HSCT

1 fter consolidation (day 100 after autologous HSCT).

2 eic hematopoietic stem cell transplantation (HSCT).

3 eic hematopoietic stem cell transplantation (HSCT).

4 is hematopoietic stem cell transplantation (HSCT).

5 llograft hematopoietic stem cell transplant (HSCT).

6 ematopoietic stem-cell transplantation (allo-HSCT).

7 ing hematopoietic stem-cell transplantation (HSCT).

8 eic hematopoietic stem cell transplantation (HSCT).

9 eic hematopoietic stem cell transplantation (HSCT).

10 in hematopoietic stem cell transplantation (HSCT).

11 oing haemopoietic stem-cell transplantation (HSCT).

12 ed haematopoietic stem-cell transplantation (HSCT).

13 of hematopoietic stem cell transplantation (HSCT).

14 onders (96.7%); 20/25 (80%) had no RD before HSCT.

15 come the major cause of death following allo-HSCT.

16 splanted HSCs will inform efforts to improve HSCT.

17 ection required liver transplantation before HSCT.

18 h her mother as the donor for both liver and HSCT.

19 r, she developed a biliary leak delaying the HSCT.

20 versus-host disease (aGvHD) development post-HSCT.

21 ) were 78.2%, 58.1%, and 72.3% 5 years after HSCT.

22 en with severe organ failure occurring after HSCT.

23 CR repertoire on clinical outcomes following HSCT.

24 and mitigating graft-versus-host disease in HSCT.

25 e poorly and do not seem to benefit from CR1 HSCT.

26 Total body irradiation was given with each HSCT.

27 (GPRASPs) function as negative regulators of HSCT.

28 ildren less than 10 years old at the time of HSCT.

29 old with high-risk ALL undergoing allogeneic HSCT.

30 m in her peripheral blood immediately before HSCT.

31 recipients of haploidentical and cord blood HSCT.

32 donor T cell expansion and mortality in allo-HSCT.

33 ure with Candida sepsis on day +40 following HSCT.

34 n mouse HSCT and ~2-fold in human xenogeneic HSCT.

35 ation and improved survival after allogeneic HSCT.

36 se of interleukin-1alpha (IL-1alpha) in allo-HSCT.

37 patients underwent myeloablation followed by HSCT.

38 ly relevant, preclinical model of allogeneic HSCT.

39 ing virus-specific T cells to patients after HSCT.

40 nt GNB was 17.3% in allo-HSCT and 9% in auto-HSCT.

41 ights into the biology of HSC recovery after HSCT.

42 re and 5 or 9, and 28 days, and 1 year after HSCT.

43 ts from the conventional care group received HSCT.

44 infection by the same microorganism in allo-HSCT.

45 ), CD19(+), and NK-cell output 15 years post-HSCT.

46 tric and adult B-ALL patients relapsed after HSCT.

47 new strategy to enhance outcomes after allo-HSCT.

48 utcome was event-free survival 2 years after HSCT.

49 currence after both allo-HSCT and autologous HSCT.

50 gnancy, must be weighed against the risks of HSCT.

51 d side effects, and when these might replace HSCT.

52 ic patients with cancer and those undergoing HSCT.

53 whether treated with conventional therapy or HSCT.

54 storically considered a contraindication for HSCT.

55 rapy for ALL, autologous HSCT and allogeneic HSCT.

56 ved chemotherapy with intent to proceed with HSCT.

57 d in the future to enhance the efficiency of HSCT.

58 ence of relapse in 41 patients who underwent HSCT (17.8% [95% CI 7.7-31.3]) was lower than in the 43

59 dence interval, 1.45-3.13; P <.001) and auto-HSCT (2.43; 1.22-4.84; P = .01).

60 At 1 year after HSCT, 3-month steroid-free clinical remission was seen i

61 than in the 43 patients who did not undergo HSCT (45.1% [28.4-60.5], p=0.013), but event-free surviv

62 yme activity normalized in those tested post-HSCT (7/7), as early as day +14 (myeloid engraftment).

63 t center reporting on VOD/SOS in consecutive HSCT adult patients (n = 530), transplanted for hematolo

64 enza RVI in a consecutive cohort of 136 allo-HSCT adult recipients who developed 161 RVI over 5 flu s

65 iology, pathology, and transfusion medicine; HSCT advanced-practice providers and medical trainees; p

66 Post-HSCT aGVHD developed with an incidence of 57.1% versus 1

67 Patients were randomized to receive HSCT along with cyclophosphamide (200 mg/kg) and antithy

68 nce of pre-engraftment GNB was 17.3% in allo-HSCT and 9% in auto-HSCT.

69 serotherapy (antithymocyte globulin) before HSCT and a short course of posttransplant immunosuppress

70 g induction chemotherapy for ALL, autologous HSCT and allogeneic HSCT.

71 overcome disease recurrence after both allo-HSCT and autologous HSCT.

72 tive surveillance to detect IFD relapse post-HSCT and careful drug selection for antifungal prophylax

73 HSCT and conventionally treated survivors had a similar

74 orted outcomes were equally impaired between HSCT and conventionally treated survivors, but poorer in

75 plasma markers were analyzed at day 100 post-HSCT and correlated with GVHD diagnosed according to the

76 ls GPRASP proteins as negative regulators of HSCT and CXCR4 activity.

77 mature NK cells, starting from day 15 after HSCT and favored by the high levels of interleukin-15 pr

78 re, we demonstrate a strategy for autologous HSCT and gene therapy utilizing a lentiviral vector (LV)

79 culiar case of a girl with aHUS complicating HSCT and her subsequent successful KTx received from the

80 agement of cytomegalovirus in patients after HSCT and in patients receiving other types of therapy fo

81 y influence the incidence of relapse after h-HSCT and optimize donor selection.

82 her establish the effectiveness of SOT after HSCT and to better understand the mechanism underlying t

83 disease who were treated with an allogeneic HSCT and to identify disease- and treatment-related fact

84 ycles of induction therapy before autologous HSCT and two 28-day cycles of consolidation therapy afte

85 ll reconstitution increased ~6-fold in mouse HSCT and ~2-fold in human xenogeneic HSCT.

86 fter haemopoietic stem cell transplantation (HSCT) and a major cause of transplant-related mortality.

87 ing hematopoietic stem-cell transplantation (HSCT) and is associated with increased morbidity and mor

88 ous hematopoietic stem cell transplantation (HSCT) and mesenchymal stromal cell therapy have been pro

89 ematopoietic stem cell transplantation (allo-HSCT) and their respective related donors (n = 42 donor-

90 ic haematopoietic stem cell transplantation (HSCT), and an increasing number of reports indicate that

91 or hematopoietic stem cell transplantation (HSCT), and that the poor PROs correlated with the presen

92 ter hematopoietic stem cell transplantation (HSCT), and updated epidemiological investigation is advi

93 ed orally twice daily starting 3 days before HSCT, and (in the absence of GVHD) tapered from day 96 t

94 patients were randomly assigned to immediate HSCT, and 22 patients were assigned to mobilisation foll

95 igher disease burden, longer duration before HSCT, and lung involvement were associated with poor out

96 -21 years at HSCT, in complete remission pre-HSCT, and with an HLA-compatible related or unrelated do

97 Broad HSCT application is currently precluded largely due to m

98 ly haematopoietic stem cell transplantation (HSCT) approaches for several genetic diseases that can b

99 ediatric hematopoietic stem cell transplant (HSCT) are understudied.

100 broad antiviral protection to recipients of HSCT as an immediately available off-the-shelf product.

101 ysplastic who progressed- two (16%) received HSCT as initial therapy and ten (83%) received chemother

102 ficant barrier against the widespread use of HSCTs as a curative modality.

103 se findings have major implications for allo-HSCT, as pharmacological interference with the caspase-1

104 of hematopoietic stem cell transplantation (HSCT) associated with excessive complement activation, l

105 Use of myeloablative regimens and HSCT at 2 years or less from diagnosis associated with h

106 acute lymphocytic leukaemia, who received a HSCT at any age from an unrelated 10/10 HLA-matched dono

107 L) of IL2RG/JAK3 SCID patients >2 years post-HSCT at our center.

108 ative conditioning and HLA-matched unrelated HSCT at the Fred Hutchinson Cancer Research Center.

109 lyzed for all boys with cALD who received an HSCT at the University of Minnesota between January 1, 1

110 In several in vivo models of allo-HSCT, ATG5-dependent dissociation of T-cell functions co

111 ollowing hematopoietic stem cell transplant (HSCT) because of various hematologic problems, including

112 eic hematopoietic stem cell transplantation (HSCT) between 1984 and 2016 was collected in 20 pediatri

113 eic hematopoietic stem cell transplantation (HSCT) between Jan 3, 2001, and Dec 31, 2015, and were re

114 or higher, and were indicated for allogeneic HSCT but considered at an increased risk for standard my

115 logeneic hematopoietic stem cell transplant (HSCT) can be curative, but suitable donors are often una

116 hematopoietic stem cell transplantation (MSD-HSCT) can reduce velocities in patients with SCA is unkn

117 randomised, phase 3 trial took place at nine HSCT centres based in the USA, Denmark, and Germany.

118 vidualize risk factors and determine optimal HSCT characteristics.

119 us haematopoietic stem-cell transplantation (HSCT) compared with mobilisation followed by conventiona

120 ith relapsing-remitting MS, nonmyeloablative HSCT, compared with DMT, resulted in prolonged time to d

121 d hepatotoxicity, especially after follow-up HSCT, compared with standard care.

122 ally reduce GVHD in cancer patients, but pre-HSCT conditioning regimens and GVHD create a challenging

123 The ASTIC trial asked whether HSCT could cure CD.

124 or 3 Gy total body irradiation on the day of HSCT (day 0).

125 Analysis of the HSCT decisions revealed the anticipated heterogeneity, f

126 were no deaths and no patients who received HSCT developed nonhematopoietic grade 4 toxicities (such

127 ed a KTx from her father who was already the HSCT donor.

128 Prioritising HSCT donors with the IFNL4-null genotype might decrease

129 ve T cells also escaped the thymus following HSCT during chronic infection.

130 rapeutic hematopoietic stem cell transplant (HSCT) during chronic infection generated new antiviral C

131 ecognized as relevant clinical variables for HSCT eligibility.

132 bcutaneously injected in mice at the time of HSCT enhanced T cell progenitor seeding of the thymus, T

133 The outcomes of novel HSCT, ERT, and HSC-GT strategies should be evaluated pro

134 pproaches might advance our understanding of HSCT events and lead to novel recommendations to enhance

135 least 16 years old, had undergone allogeneic HSCT for a hematological malignancy, and had available p

136 collected data on 130 patients who underwent HSCT for CD40L deficiency between 1993-2015.

137 ells infused before and after haploidentical HSCT for high-risk myeloid malignancies.

138 ult infected with HIV-1 underwent allogeneic HSCT for Hodgkin's lymphoma using cells from a CCR5Delta

139 The outcome after HSCT for IEM depends on HLA match, year and immune femal

140 ine as a conditioning regimen for allogeneic HSCT for older or comorbid patients with acute myeloid l

141 t after haematopoietic stem cell transplant (HSCT) for patients with refractory CD.

142 low-up, 10 years; range, 1-52), 24 underwent HSCT from 2005 to 2019.

143 We assessed 404 patients (who had a HSCT from Jan 9, 2004, to Dec 26, 2008) in the discovery

144 n 20% lower (IQR, 7.3%-40.3%) than their pre-HSCT GFR.

145 se progression occurred in 3 patients in the HSCT group and 34 patients in the DMT group.

146 ecreased (improved) from 3.38 to 2.36 in the HSCT group and increased (worsened) from 3.31 to 3.98 in

147 o progression could not be calculated in the HSCT group because of too few events; it was 24 months (

148 9.3% and 29.3% +/- 10.1%, respectively, and HSCT had no significant impact on outcomes.

149 er haematopoietic stem cell transplantation (HSCT) had been done, as well as treatment outcomes, incl

150 logical malignancies treatable by allogeneic HSCT, had a Karnofsky score greater than or equal to 60,

151 ter hematopoietic stem cell transplantation (HSCT) has been studied, little is known about the role o

152 wing haemopoietic stem cell transplantation (HSCT) has historically been limited by infrequent marrow

153 Patients with CD who are eligible for HSCT have typically been failed by most approved therapi

154 increased mortality at 4 months both in allo-HSCT (hazard ratio, 2.13; 95% confidence interval, 1.45-

155 CI, 20.4 to 1,091.9) and among those without HSCT (hazard ratio, 92.7; 95% CI, 12.4 to 690.7).

156 Post-HSCT hematological autoimmunity (cytopenias) was reporte

157 cases, neurological worsening continued post-HSCT; however, the progression in cognitive deficits, ov

158 Hematopoietic stem cell transplantation (HSCT) improves clinical outcomes in KD patients only if

159 th inherited diseases, who were treated with HSCT in 3 decades.

160 disease control served as indication for the HSCT in 4 patients and myelodysplastic syndrome developm

161 ary, after >2 years of follow-up, allogeneic HSCT in ALSP led to interval resolution of diffusion MRI

162 We now assess HSCT in patients enrolled in the ASTIC trial using endpo

163 ly diagnosis have improved IFD outcomes, and HSCT in patients with a recent IFD has become increasing

164 was assessed prospectively in patients after HSCT in the absence of GVHD.

165 OS of 63%, which in principle justifies allo-HSCT in these patients.

166 eic hematopoietic stem cell transplantation (HSCT) in autoinflammatory disorders, including PAMI synd

167 or haematopoietic stem cell transplantation (HSCT) in children (offering an overall survival rate of

168 ort hematopoietic stem cell transplantation (HSCT) in patients with severe presentation of LPS-respon

169 eic hematopoietic stem cell transplantation (HSCT) in pediatric patients with acute lymphoblastic leu

170 ic haematopoietic stem cell transplantation (HSCT) in two patients with ALSP at the University of Cal

171 ents <= 18 years at diagnosis, 4-21 years at HSCT, in complete remission pre-HSCT, and with an HLA-co

172 rall, we evaluated data on 44 SOTs following HSCT including 20 liver (LTx), 12 lung (LuTx), 6 heart (

173 severe and drug-refractory infections after HSCT, including infections from two viruses (BKV and HHV

174 overall survival in patients with follow-up HSCT (inotuzumab ozogamicin vs standard care) was 1.227

175 HSCT is curative in patients with CD40L deficiency, with

176 ing a treatment option for patients for whom HSCT is not applicable.

177 Allo-HSCT is safe and effective in young adult patients with

178 eic hematopoietic stem cell transplantation (HSCT) is a critically important therapy for hematologica

179 Hematopoietic stem cell transplantation (HSCT) is a curative therapy for blood and immune disease

180 eic hematopoietic stem cell transplantation (HSCT) is a curative treatment for multiple disorders, bu

181 neic haemopoietic stem cell transplantation (HSCT) is an unmet medical need for the growing number of

182 neic haemopoietic stem cell transplantation (HSCT) is associated with considerable morbidity and mort

183 ter hematopoietic stem cell transplantation (HSCT) is complex.

184 ematopoietic stem cell transplantation (allo-HSCT) is limited by GVHD.

185 matopoietic stem cell (HSC) transplantation (HSCT) is often exploited to treat hematologic disease.

186 and hematopoietic stem-cell transplantation (HSCT) is often pursued in first complete remission (CR1)

187 eic hematopoietic stem cell transplantation (HSCT) is still hampered by high morbidity and mortality

188 eic hematopoietic stem cell transplantation (HSCT) is the only cure.

189 tic hematopoietic stem cell transplantation (HSCT) is the only treatment for infantile-onset GLD; how

190 eic hematopoietic stem cell transplantation (HSCT) is used as a therapeutic approach for primary immu

191 and 1245 patients in the validation dataset (HSCT Jan 7, 2000, to Dec 26, 2008).

192 ts with MRD of 10(-3) or greater before allo-HSCT (late nonresponders) still had an EFS of 50% and OS

193 complex decision making involved in the peri-HSCT management of these patients.

194 Allo-HSCT markedly increases the LPS-caspase-11 interaction,

195 Allogeneic HSCT may be beneficial in ALSP by providing a supply of

196 although relatively uncommon, NC after allo-HSCT, may become more frequent due to the improved overa

197 The overall survival rate after HSCT (median follow-up, 20 months) was 70.8% (17 of 24 p

198 FS (56%), and their MRD persisted until allo-HSCT more frequently than it did in patients with MRD of

199 ivors of childhood hematologic malignancies (HSCT N = 112 [70% allogeneic, 30% autologous]; conventio

200 MSD-HSCT (n = 32), compared with standard care (n = 35) (tra

201 With a median follow-up time since allo-HSCT of 16 years (range, 10-32 years), we found a total

202 ous hematopoietic stem cell transplantation (HSCT) of gene-modified cells is an alternative to enzyme

203 ch is warranted to assess the effects of MSD-HSCT on clinical outcomes and over longer follow-up.

204 Group (COG) trials to evaluate the impact of HSCT on outcome.

205 who received standard care and proceeded to HSCT, one (3%) had (non-fatal) sinusoidal obstruction sy

206 tched sibling donor/HLA-matched family donor HSCT or HSC-GT are not available or have failed, ERT can

207 Associations with post-HSCT overall survival were as follows: HR 1.24, 95% CI 1

208 perts including physicians with expertise in HSCT, paediatric intensive care, nephrology, hepatology,

209 protocol to diagnose retinitis in pediatric HSCT patients in the early, often asymptomatic stage.

210 ter of CMV retinitis in pediatric allogeneic HSCT patients may suggest a rise in incidence of CMV ret

211 laxis administration in pediatric cancer and HSCT patients.

212 luated fidaxomicin for prevention of CDAD in HSCT patients.

213 laxis administration in pediatric cancer and HSCT patients.

214 HCMV in hematopoietic stem cell transplant (HSCT) patients soluble Gal-9 is upregulated.

215 ation from pediatric hematology/oncology and HSCT, pediatric infectious diseases (including antibioti

216 ation from pediatric hematology/oncology and HSCT, pediatric infectious diseases (including antibioti

217 Haploidentical-related donor HSCT performed 2 months after liver transplantation was

218 Soon after HSCT performed for acute lymphoblastic leukemia, the pat

219 , there was no difference in the outcomes of HSCT performed from MUD and MMRD.

220 after reduced intensity conditioning PBSC h-HSCT, perhaps because of the combined effect of T and NK

221 ost-hematopoietic stem cell transplantation (HSCT) period, IFDs, especially invasive mold diseases, w

222 eic hematopoietic stem cell transplantation (HSCT), posing as a significant barrier against the wides

223 oid leukemia, to those undergoing allogeneic HSCT pre-engraftment, and to those receiving systemic im

224 hese results suggest that CD117-ADC-mediated HSCT pre-treatment could serve as a non-myeloablative co

225 medicine techniques to assess the phases of HSCT: pre-transplant homoeostasis, induced aplasia, earl

226 many considerations inherent to planning for HSCT preceded by liver transplant in patients with prima

227 Mortality occurred mainly early after HSCT, predominantly from infections.

228 ic haematopoietic stem-cell transplantation (HSCT) procedures using a donor with a homozygous mutatio

229 Jan 1, 2000, and Dec 31, 2008, and had a pre-HSCT recipient or donor blood sample available.

230 Most HSCT recipients lose their immunity to various pathogens

231 ile-onset GLD; however, clinical outcomes of HSCT recipients often remain poor, and procedure-related

232 Another challenge is to provide HSCT recipients the same level of vaccine protection as

233 A total of 234 allo-HSCT recipients were studied; postengraftment CDI develo

234 We present our experience with 64 pediatric HSCT recipients who had high-risk TA-TMA (hrTA-TMA) and

235 cination may have a clinical benefit in allo-HSCT recipients with virologically-confirmed RVI, in ter

236 Among 297 allogeneic HSCT recipients, 85 (28.7%) were HBsAg-negative, anti-HB

237 non-relapse mortality, except in cord blood HSCT recipients, who had a lower relapse incidence.

238 gnificantly reduced the incidence of CDAD in HSCT recipients.

239 4 episodes (46%) of influenza RVI in 70 allo-HSCT recipients.

240 ration in pediatric patients with cancer and HSCT recipients.

241 laxis in children and adults with cancer and HSCT recipients.

242 ature in hematopoietic stem cell transplant (HSCT) recipients with transplant-associated thrombotic m

243 ematopoietic stem cell transplantation (allo-HSCT) recipients, its clinical benefits are still uncert

244 ize that the restricted temporal efficacy of HSCT reflects a requirement for GALC in early brain deve

245 Long-term safety of the low intensity HSCT regimen forms the primary endpoint for the EBMT fol

246 ase in 16 children (36.3%), acute or chronic HSCT-related toxicity in 18 (40.9%), and organ dysfuncti

247 eic hematopoietic stem cell transplantation (HSCT) remains the only treatment option for several seve

248 The HSCT represents a good marker of cognitive inhibition im

249 Hematopoietic stem cell transplantation (HSCT) represents a potentially useful approach to slow o

250 Optimal timing of HSCT requires careful evaluation of the available effect

251 At 28 and 26 months post-HSCT, respectively, both patients were alive, without ev

252 Allogeneic HSCT seems to be an effective option to cure cytopenia a

253 eic hematopoietic stem cell transplantation (HSCT) should be pursued.

254 ative regimens based on age (>=50 years), an HSCT-specific comorbidity index of more than 2, or both.

255 ork Hematopoietic Stem Cell Transplantation (HSCT) Subgroup and the MD Anderson Cancer Center CAR T C

256 ignificant improvement to 66% in 1-year post-HSCT survival in treated patients from our previously re

257 same hrTA-TMA features that had 1-year post-HSCT survival of 16.7%.

258 recipient and donor IFNL4 genotype with post-HSCT survival outcomes in patients with acute leukaemia.

259 veals that compared with noncancer controls, HSCT survivors endorsed a significantly higher symptom p

260 om domains and HRQOL (all P > .05); however, HSCT survivors had a significantly higher cumulative pre

261 Of 17 HSCT survivors, 7 are in complete remission and 5 are in

262 Sirolimus was started 3 days before HSCT, taken orally at 2 mg once daily and adjusted to ma

263 significantly lower in patients who survived HSCT than in those receiving conventional treatment (P =

264 yme replacement therapy (ERT) and allogeneic HSCT that has shown clinical benefit for adenosine deami

265 ive hematopoietic stem cell transplantation (HSCT), the donor being her haploidentical mother.

266 encouraging outcomes after alternative donor HSCT, the new challenge is to risk stratify patients, re

267 Among those whose initial treatment excluded HSCT, the rate remained elevated more than 5 years from

268 higher error scores (part B) but equivalent HSCT time to completion (part B-part A) compared to C9-

269 HSCT time to completion significantly predicted the prox

270 Anatomically, we found that HSCT time to completion was associated with the integrit

271 t with the Hayling Sentence Completion Test (HSCT; time to completion (part B-part A); error score in

272 ges, designed to expand eligibility for allo-HSCT to older patients and/or those with comorbidities,

273 ldhood hematologic malignancies treated with HSCT to those treated with conventional therapy and nonc

274 high-risk chemotherapy regimens and frequent HSCT upon first remission.

275 eic hematopoietic stem cell transplantation (HSCT) using donor-derived CD19 CAR T cells generated wit

276 onal follow-up, and randomised to autologous HSCT versus standard care (ratio 2:1).

277 After 5.5 months, a second HSCT was performed from an alternative donor.

278 a sequential liver transplant followed by a HSCT was planned with her mother as the donor for both l

279 of persistently elevated TCD velocities, MSD-HSCT was significantly associated with lower TCD velocit

280 eic hematopoietic stem cell transplantation (HSCT) was monitored.

281 ematopoietic stem cell transplantation (allo-HSCT) was the first successful therapy for patients with

282 Hematopoietic stem cell transplantation (HSCT) was used as consolidation in 29/30 responders (96.

283 Outcomes for patients undergoing CR1 HSCT were not significantly improved: 5-year EFS and OS

284 ematopoietic stem cell transplantation (allo-HSCT), which is an effective therapy for hematopoietic m

285 MV induces global myelosuppression following HSCT while maintaining lifelong infection in myeloid lin

286 eic hematopoietic stem-cell transplantation (HSCT) will require efforts to decrease treatment-related

287 ction of early subclinical engraftment after HSCT with (18)F-FLT PET or CT.

288 d, ERT can be continued or reinstituted, and HSCT with alternative donors should be considered.

289 d a reduced intensity conditioning to PBSC h-HSCT with cyclosporine and mycophenolate mofetyl + PTCY

290 All patients were prepared for HSCT with fludarabine (30 mg/m(2) per day) 4, 3, and 2 d

291 this double-blind study, subjects undergoing HSCT with fluoroquinolone prophylaxis stratified by tran

292 these data suggest that a single allogeneic HSCT with homozygous CCR5Delta32 donor cells may be suff

293 ents with PAMI syndrome underwent allogeneic HSCT with myeloablative (4) or reduced-intensity (1) con

294 nrolled on a trial of reduced-intensity allo-HSCT with standard GVHD prophylaxis plus maraviroc to a

295 s, in the absence of HLA-identical siblings, HSCT with TCRalphabeta+/CD19+ graft depletion from MMRDs

296 diatric patients with various PIDs underwent HSCT with TCRalphabeta+/CD19+ graft depletion from MUDs

297 studies are required to compare the risks of HSCT with those of lifelong supportive therapy.

298 us haematopoietic stem-cell transplantation (HSCT) with daratumumab plus bortezomib, thalidomide, and

299 l hematopoietic stem cell transplantation (h-HSCT) with posttransplant cyclophosphamide (PTCY) using

300 of hematopoietic stem cell transplantation (HSCT) with TCRalphabeta+/CD19+ depletion from matched un

301 vivo-expanded NK cells after haploidentical HSCT without adverse effects, increased GVHD, or higher